메뉴 건너뛰기




Volumn 61, Issue 4, 2014, Pages 461-467

PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer

Author keywords

Breast cancer; Docetaxel; Epirubicin; NCT; PIK3CA somatic mutation

Indexed keywords

B RAF KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

EID: 84904392089     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_057     Document Type: Article
Times cited : (12)

References (30)
  • 1
    • 33645461582 scopus 로고    scopus 로고
    • Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results
    • BERIWAL S, SCHWARTZ GF, KOMARNICKY L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 12: 159-164. http://dx.doi.org/10.1111/j.1075-122X.2006.00225.x
    • (2006) Breast J , vol.12 , pp. 159-164
    • Beriwal, S.1    Schwartz, G.F.2    Komarnicky, L.3    Garcia-Young, J.A.4
  • 2
    • 27944503994 scopus 로고    scopus 로고
    • High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer
    • ABRIAL SC, Penault-Llorca F, DELVA R, BOUGNOUX P, LEDUC B ET AL. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005; 94: 255-263. http://dx.doi.org/10.1007/s10549-005-9008-8
    • (2005) Breast Cancer Res Treat , vol.94 , pp. 255-263
    • Abrial, S.C.1    Penault-Llorca, F.2    Delva, R.3    Bougnoux, P.4    Leduc, B.5
  • 3
    • 53049100145 scopus 로고    scopus 로고
    • Predictive markers of response to neoadjuvant chemotherapy in breast cancer
    • TEWARI M, KRISHNAMURTHY A, SHUKLA HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 2008; 17: 301-311. http://dx.doi.org/10.1016/j.suronc.2008.03.003
    • (2008) Surg Oncol , vol.17 , pp. 301-311
    • Tewari, M.1    Krishnamurthy, A.2    Shukla, H.S.3
  • 4
    • 32144435972 scopus 로고    scopus 로고
    • The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer
    • HIRANO A, SHIMIZU T, IMAMURA H, WATANABE O, KINOSHITA J ET AL. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer. Anticancer Res 2006; 26: 581-584.
    • (2006) Anticancer Res , vol.26 , pp. 581-584
    • Hirano, A.1    Shimizu, T.2    Imamura, H.3    Watanabe, O.4    Kinoshita, J.5
  • 5
    • 84655176743 scopus 로고    scopus 로고
    • ER, PgR, HER-2, Ki-67, topoisomerase IIalpha, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer
    • LI XR, LIU M, ZHANG YJ, WANG JD, ZHENG YQ ET AL. ER, PgR, HER-2, Ki-67, topoisomerase IIalpha, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med Oncol 2011; 28 Suppl 1: S48-54. http://dx.doi.org/10.1007/s12032-010-9693-y
    • (2011) Med Oncol , vol.28 , Issue.SUPPL. 1
    • Li, X.R.1    Liu, M.2    Zhang, Y.J.3    Wang, J.D.4    Zheng, Y.Q.5
  • 6
    • 77954832064 scopus 로고    scopus 로고
    • Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: Clinical analysis of 160 cases
    • LI XR, WANG JD, ZHANG YJ, KONG QL, MA B ET AL. Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases. Zhonghua Yi Xue Za Zhi 2009; 89: 87-90.
    • (2009) Zhonghua Yi Xue Za Zhi , vol.89 , pp. 87-90
    • Li, X.R.1    Wang, J.D.2    Zhang, Y.J.3    Kong, Q.L.4    Ma, B.5
  • 7
    • 84857916102 scopus 로고    scopus 로고
    • TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in highrisk breast cancer patients
    • HERTEL PB, TU D, EJLERTSEN B, JENSEN MB, BALSLEV E ET AL. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in highrisk breast cancer patients. Breast Cancer Res Treat 2012; 132: 225-234. http://dx.doi.org/10.1007/s10549-011-1896-1
    • (2012) Breast Cancer Res Treat , vol.132 , pp. 225-234
    • Hertel, P.B.1    Tu, D.2    Ejlertsen, B.3    Jensen, M.B.4    Balslev, E.5
  • 8
    • 77949895996 scopus 로고    scopus 로고
    • HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients
    • EJLERTSEN B, JENSEN MB, NIELSEN KV, BALSLEV E, RASMUSSEN BB ET AL. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010; 28: 984-990. http://dx.doi.org/10.1200/JCO.2009.24.1166
    • (2010) J Clin Oncol , vol.28 , pp. 984-990
    • Ejlertsen, B.1    Jensen, M.B.2    Nielsen, K.V.3    Balslev, E.4    Rasmussen, B.B.5
  • 9
    • 79957820567 scopus 로고    scopus 로고
    • HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    • YAO L, LIU Y, LI Z, OUYANG T, LI J ET AL. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol 2011; 22: 1326-1331. http://dx.doi.org/10.1093/annonc/mdq612
    • (2011) Ann Oncol , vol.22 , pp. 1326-1331
    • Yao, L.1    Liu, Y.2    Li, Z.3    Ouyang, T.4    Li, J.5
  • 10
    • 84055213629 scopus 로고    scopus 로고
    • Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
    • JACOT W, Lopez-Crapez E, THEZENAS S, SENAL R, FINA F ET AL. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res 2011; 13: R133. http://dx.doi.org/10.1186/bcr3079
    • (2011) Breast Cancer Res , vol.13
    • Jacot, W.1    Lopez-Crapez, E.2    Thezenas, S.3    Senal, R.4    Fina, F.5
  • 11
    • 84862526929 scopus 로고    scopus 로고
    • The clonal and mutational evolution spectrum of primary triplenegative breast cancers
    • SHAH SP, ROTH A, GOYA R, OLOUMI A, HA G ET AL. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012; 486: 395-399260.
    • (2012) Nature , vol.486 , pp. 395-399260
    • Shah, S.P.1    Roth, A.2    Goya, R.3    Oloumi, A.4    Ha, G.5
  • 12
    • 51049118140 scopus 로고    scopus 로고
    • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    • Stemke-Hale K, Gonzalez-Angulo AM, LLUCH A, NEVE RM, KUO WL ET AL. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091. http://dx.doi.org/10.1158/0008-5472.CAN-07-6854
    • (2008) Cancer Res , vol.68 , pp. 6084-6091
    • Stemke-Hale, K.1    Gonzalez-Angulo, A.M.2    Lluch, A.3    Neve, R.M.4    Kuo, W.L.5
  • 13
    • 16644393213 scopus 로고    scopus 로고
    • The PIK3CA gene is mutated with high frequency in human breast cancers
    • BACHMAN KE, ARGANI P, SAMUELS Y, SILLIMAN N, PTAK J ET AL. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772-775. http://dx.doi.org/10.4161/cbt.3.8.994
    • (2004) Cancer Biol Ther , vol.3 , pp. 772-775
    • Bachman, K.E.1    Argani, P.2    Samuels, Y.3    Silliman, N.4    Ptak, J.5
  • 14
    • 84856767715 scopus 로고    scopus 로고
    • PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2based subgroups
    • CIZKOVA M, SUSINI A, VACHER S, Cizeron-Clairac G, ANDRIE UC et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2based subgroups. Breast Cancer Research 2012; 14: R28. http://dx.doi.org/10.1186/bcr3113
    • (2012) Breast Cancer Research , vol.14
    • Cizkova, M.1    Susini, A.2    Vacher, S.3    Cizeron-Clairac, G.4    Andrieu, C.5
  • 15
    • 35148854641 scopus 로고    scopus 로고
    • PI3 kinase activation and response to Trastuzumab Therapy: What's neu with herceptin resistance?
    • PARK BH, DAVIDSON NE. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell. 2007; 12: 297-299. http://dx.doi.org/10.1016/j.ccr.2007.10.004
    • (2007) Cancer Cell , vol.12 , pp. 297-299
    • Park, B.H.1    Davidson, N.E.2
  • 16
    • 84864945212 scopus 로고    scopus 로고
    • PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
    • JENSEN JD, KNOOP A, LAENKHOLM AV, GRAUSLUND M, JENSEN MB ET AL. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012; 23: 2034-2042. http://dx.doi.org/10.1093/annonc/mdr546
    • (2012) Ann Oncol , vol.23 , pp. 2034-2042
    • Jensen, J.D.1    Knoop, A.2    Laenkholm, A.V.3    Grauslund, M.4    Jensen, M.B.5
  • 17
    • 79960980007 scopus 로고    scopus 로고
    • Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    • GOLDHIRSCH A, WOOD WC, COATES AS, GELBER RD, THURLIMANN B ET AL. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747. http://dx.doi.org/10.1093/annonc/mdr304
    • (2011) Ann Oncol , vol.22 , pp. 1736-1747
    • Goldhirsch, A.1    Wood, W.C.2    Coates, A.S.3    Gelber, R.D.4    Thurlimann, B.5
  • 18
    • 0017348988 scopus 로고
    • Assessment of response to therapy in advanced breast cancer
    • HAYWARD JL, CARBONE PP, HEUSEN JC, KUMAOKA S, SEGALOFF A ET AL. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-298. http://dx.doi.org/10.1038/bjc.1977.42
    • (1977) Br J Cancer , vol.35 , pp. 292-298
    • Hayward, J.L.1    Carbone, P.P.2    Heusen, J.C.3    Kumaoka, S.4    Segaloff, A.5
  • 19
    • 0033050164 scopus 로고    scopus 로고
    • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    • KUERER HM, NEWMAN LA, SMITH TL, AMES FC, HUNT KK ET AL. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
    • (1999) J Clin Oncol , vol.17 , pp. 460-469
    • Kuerer, H.M.1    Newman, L.A.2    Smith, T.L.3    Ames, F.C.4    Hunt, K.K.5
  • 20
    • 79952085858 scopus 로고    scopus 로고
    • A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue
    • LI G, LUO X, HE J, ZHU Z, YU G et al. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 2011; 49: 191-195. http://dx.doi.org/10.1515/CCLM.2011.040
    • (2011) Clin Chem Lab Med , vol.49 , pp. 191-195
    • Li, G.1    Luo, X.2    He, J.3    Zhu, Z.4    Yu, G.5
  • 21
    • 33646021021 scopus 로고    scopus 로고
    • A multiplex branched DNA assay for parallel quantitative gene expression profiling
    • FLAGELLA M, BUI S, ZHENG Z, NGUYEN CT, ZHANG A ET AL. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal Biochem 2006; 352: 50-60. http://dx.doi.org/10.1016/j.ab.2006.02.013
    • (2006) Anal Biochem , vol.352 , pp. 50-60
    • Flagella, M.1    Bui, S.2    Zheng, Z.3    Nguyen, C.T.4    Zhang, A.5
  • 22
    • 84860389233 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy
    • TENG YH, TAN WJ, THIKE AA, CHEOK PY, TSE GM ET AL. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011; 13: R35. http://dx.doi.org/10.1186/bcr2857
    • (2011) Breast Cancer Res , vol.13
    • Teng, Y.H.1    Tan, W.J.2    Thike, A.A.3    Cheok, P.Y.4    Tse, G.M.5
  • 23
    • 69349105634 scopus 로고    scopus 로고
    • PIK3CA mutation associates with improved outcome in breast cancer
    • KALINSKY K, JACKS LM, HEGUY A, PATIL S, DROBNJAK M ET AL. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15: 5049-5059. http://dx.doi.org/10.1158/1078-0432.CCR-09-0632
    • (2009) Clin Cancer Res , vol.15 , pp. 5049-5059
    • Kalinsky, K.1    Jacks, L.M.2    Heguy, A.3    Patil, S.4    Drobnjak, M.5
  • 24
    • 84863338519 scopus 로고    scopus 로고
    • PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    • JANKU F, WHELER JJ, WESTIN SN, MOULDER SL, NAING A ET AL. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782. http://dx.doi.org/10.1200/JCO.2011.36.1196
    • (2012) J Clin Oncol , vol.30 , pp. 777-782
    • Janku, F.1    Wheler, J.J.2    Westin, S.N.3    Moulder, S.L.4    Naing, A.5
  • 25
    • 3042622482 scopus 로고    scopus 로고
    • HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
    • OWENS MA, HORTEN BC, DA SILVA MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5: 63-69. http://dx.doi.org/10.3816/CBC.2004.n.011
    • (2004) Clin Breast Cancer , vol.5 , pp. 63-69
    • Owens, M.A.1    Horten, B.C.2    Da Silva, M.M.3
  • 26
    • 33947207819 scopus 로고    scopus 로고
    • HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally 300 advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination
    • TIEZZI DG, ANDRADE JM, Ribeiro-Silva A, ZOLA FE, MARANA HR ET AL. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally 300 advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7: 36. http://dx.doi.org/10.1186/1471-2407-7-36
    • (2007) BMC Cancer , vol.7 , pp. 36
    • Tiezzi, D.G.1    Andrade, J.M.2    Ribeiro-Silva, A.3    Zola, F.E.4    Marana, H.R.5
  • 27
    • 84862303759 scopus 로고    scopus 로고
    • Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
    • VON MINCKWITZ G, UNTCH M, BLOHMER JU, COSTA SD, EIDTMANN H ET AL. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804304. http://dx.doi.org/10.1200/JCO.2011.38.8595
    • (2012) J Clin Oncol , vol.30 , pp. 1796-1804304
    • Von Minckwitz, G.1    Untch, M.2    Blohmer, J.U.3    Costa, S.D.4    Eidtmann, H.5
  • 28
    • 84861527388 scopus 로고    scopus 로고
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    • CURTIS C, SHAH SP, CHIN SF, TURASHVILI G, RUEDA OM ET AL. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
    • (2012) Nature , vol.486 , pp. 346-352
    • Curtis, C.1    Shah, S.P.2    Chin, S.F.3    Turashvili, G.4    Rueda, O.M.5
  • 29
    • 35948964043 scopus 로고    scopus 로고
    • Different prognostic roles of 308 mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
    • BARBARESCHI M, BUTTITTA F, FELICIONI L, COTRUPI S, BARASSI F ET AL. Different prognostic roles of 308 mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13: 6064-6069. http://dx.doi.org/10.1158/1078-0432.CCR-07-0266
    • (2007) Clin Cancer Res , vol.13 , pp. 6064-6069
    • Barbareschi, M.1    Buttitta, F.2    Felicioni, L.3    Cotrupi, S.4    Barassi, F.5
  • 30
    • 77951884331 scopus 로고    scopus 로고
    • Association Between Gain-Of-Function Mutations In Pik3ca And Resistance To Her2-Targeted Agents In Her2-Amplified Breast Cancer Cell Lines
    • KATAOKA Y, MUKOHARA T, SHIMADA H, SAIJO N, HIRAI M ET AL. Association Between Gain-Of-Function Mutations In Pik3ca And Resistance To Her2-Targeted Agents In Her2-Amplified Breast Cancer Cell Lines. Ann Oncol 2010; 21: 255-262. http://dx.doi.org/10.1093/annonc/mdp304
    • (2010) Ann Oncol , vol.21 , pp. 255-262
    • Kataoka, Y.1    Mukohara, T.2    Shimada, H.3    Saijo, N.4    Hirai, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.